Evidence map›Paper›PMID 35606883›Full record

ArticleTrials2022

Evolocumab administration prior to Coronary Artery Bypass Grafting in patients with multivessel coronary artery disease (EVOCABG): study protocol for a randomized controlled clinical trial.

Hye Rim Na, O Sung Kwon, Joon Kyu Kang, Yong Han Kim, Ju Yong Lim

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06730802 (Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06730802 nanot yet recruitingstarted 2025, after this paper: background citation

Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)

Ran2025Enrolled400Registered outcomes2Posted comparisons0ConditionsCoronary Heart Disease, Myocardial Ischaemic SyndromeArmsPCSK9 inhibitor, Statin
PMID 38337601PMID 33197560other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hye Rim Na *Department of Cardiothoracic Surgery, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Republic of Korea.
O Sung Kwon *Department of Cardiology, The Catholic University of Korea Eunpyeong St. Mary's Hospital, Seoul, Republic of Korea.
Joon Kyu KangDepartment of Cardiothoracic Surgery, The Catholic University of Korea Eunpyeong St. Mary's Hospital, Seoul, Republic of Korea.
Yong Han KimDepartment of Cardiothoracic Surgery, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Republic of Korea.
Ju Yong LimDepartment of Cardiothoracic Surgery, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Republic of Korea. millalim92@gmail.com.ORCID http://orcid.org/0000-0002-2864-1630
The Catholic University of Korea Seoul St. Mary's Hospital · KRCatholic University of Korea · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite advances in surgical and postoperative care, myocardial injury or infarction (MI) is still a common complication in patients undergoing coronary artery bypass surgery (CABG). Several studies that aimed to reduce postoperative myocardial injury, including those investigating statin loading, have been conducted but did not indicate any clear benefits. Evolocumab, a PCSK9 inhibitor, has been reported to lower lipids and prevent ischemic events in various medical conditions. However, the effect of evolocumab in cardiovascular surgery has not been evaluated. The objective of this trial is to evaluate the cardioprotective effects of evolocumab in elective CABG patients with multivessel coronary artery disease.

methodsEVOCABG is a prospective, randomized, open, controlled, multicenter, superiority, phase III clinical trial. Patients with multivessel coronary artery disease without initial cardiac enzyme elevation will be recruited (n=100). Participants will be randomly allocated into two groups: a test group (evolocumab (140mg) administration once within 72 h before CABG) and a control group (no administration). The primary outcome is the change in peak levels of serum cardiac marker (troponin-I) within 3 days of CABG surgery compared to the baseline. Secondary outcomes include post-operative clinical events including death, myocardial infarction, heart failure, stroke, and atrial fibrillation. DISCUSSION: This trial is the first prospective randomized controlled trial to demonstrate the efficacy of evolocumab in reducing ischemic-reperfusion injury in patients undergoing CABG. This trial will provide the first high-quality evidence for preoperative use of evolocumab in mitigating or preventing ischemic-reperfusion-related myocardial injury during the surgery.

trial registrationClinical Research Information Service (CRIS) of the Republic of Korea KCT0005577 . Registered on 4 November 2020.

Indexed as

Coronary Artery DiseaseMyocardial InfarctionAntibodies, Monoclonal, HumanizedClinical Trials, Phase III as TopicCoronary Artery BypassEquivalence Trials as TopicHumansMulticenter Studies as TopicProprotein Convertase 9Prospective StudiesRandomized Controlled Trials as TopicTreatment OutcomeAntibodies, Monoclonal, HumanizedevolocumabPCSK9 protein, humanProprotein Convertase 9Coronary artery bypass graftingCoronary artery diseaseEvolocumabIschemia-reperfusion injuryMajor adverse cardiovascular eventsPCSK9 inhibitor

Identifiers

PMID35606883
PMCPMC9125921
OpenAlexW4281385813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.